Drug Profile
Gavocabtagene autoleucel - TCR2 Therapeutics
Alternative Names: Gavo-cel; Gavocabtagene autoleucel; TC 210; TC-210 T cellsLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator TCR2 Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cholangiocarcinoma; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 11 Mar 2024 Harpoon Therapeutics has been acquired by Merck & Co
- 02 Jun 2023 Efficacy and adverse events data from phase-I/II trial in Malignant mesothelioma and Ovarian cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 01 Jun 2023 TCR2 Therapeutics has been acquired by Adaptimmune